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Hepatocyte growth factor: Renotropic role and potential thera- unrecognized. Understanding the molecular mechanisms
peutics for renal diseases. Hepatocyte growth factor (HGF), a involved in regeneration systems will lead to new clinical
ligand for the c-Met receptor tyrosine kinase, has mitogenic, strategies to combat renal disease, as is now the case for
motogenic, anti-apoptotic, and morphogenic (for example, in-
the immune and neuroendocrine systems.duction of branching tubulogenesis) activities for renal tubular
Patterns of tissue regeneration are mainly divided intocells, while it has angiogenic and angioprotective actions for
two distinct systems. One is the “stem cell system.” Inendothelial cells. Stromal cells such as mesangial cells, endothe-
lial cells, and macrophages are sources of renal HGF; thus, tissues, such as nervous and muscle, stem cells usually
HGF mediates epithelial–stromal and endothelial–mesangial remain in a quiescent and undifferentiated state (but
interactions in the kidney. In response to acute renal injury, committed to differentiate into specific cell types), yet
the expression of HGF increases in the injured kidney and in
they proliferate to produce daughter cells that will differ-distant intact organs such as the lung and spleen. Locally and
entiate into the required tissues, in response to injuries.systemically increased HGF supports renal regeneration, possi-
The other is a “simple duplication system.” In parenchy-bly not only by enhancing cell growth but also by promoting
morphogenesis of renal tissue. During progression of chronic mal organs such as the kidney and liver, differentiated
renal failure/renal fibrosis, the expression of HGF decreases cells proliferate without dedifferentiation to replace ex-
in a manner reciprocal to the increase in expression of trans- cised or injured tissues. Thus, to understand mechanismsforming growth factor-b (TGF-b), a key player in tissue fibrosis.
involved in renal and hepatic regeneration, the followingA decrease in endogenous HGF, as well as increase in TGF-b,
issues must be addressed: (1) how differentiated cellsaugments susceptibility to the onset of chronic renal failure/
recognize injury or partial removal of tissues even thoughrenal fibrosis. On the other hand, supplements of exogenous
HGF have preventive and therapeutic effects in cases of acute the remaining cells are apparently intact; (2) which tropic
and chronic renal failure/renal fibrosis in laboratory animals. factors are responsible for regeneration; and (3) how
HGF prevents epithelial cell death and enhances regeneration differentiated cells proliferate and reorganize tissue-spe-and remodeling of renal tissue with injury or fibrosis. A reno-
cific multicellular architectures.tropic system underlies the vital potential of the kidney to
Both the kidney and the liver have a vital capacity toregenerate, while an impaired renotropic system may confer
regenerate. After unilateral nephrectomy, a compensa-susceptibility to the onset of renal diseases. Thus, HGF supple-
mentation may be one therapeutic strategy to treat subjects tory renal enlargement occurs and blood-borne “reno-
with renal diseases, as it enhances the intrinsic ability of the tropin” is present that enhances renal regeneration [1, 2].
kidney to regenerate. Although renotropin(s) has yet to be clearly identified,
the renotropic system is considered to support the intrin-
sic ability of the kidney to regenerate in response to
Animals, including mammals, share the intrinsic abil- injury. Studies done in the 1990s have shown that hepato-
ity to regenerate specific tissues and organs. This unique cyte growth factor (HGF) qualifies as a candidate for
potential to regenerate damaged or lost tissues is a bio- renotropin. An increase and a decrease in expression of
logical defense system, and many therapies depend on renotropic HGF are respectively involved in renal regen-
the intrinsic regeneration potential (for example, treat- eration and susceptibility to the onset of diseases such
ment for bone fracture), although this notion often goes as fibrosis of the kidney. This review focuses on the
renotropic functions of HGF for renal regeneration/pro-
tection and the potential of HGF to treat humans with
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Fig. 1. Schematic structures. (A) Prohepato-
cyte growth factor (HGF) and mature HGF.
(B) Typical biological activities of HGF medi-
ated by c-Met/HGF receptor and intracellular
signal transducers which associate with tyro-
sine-phosphorylated c-Met.
differentiated hepatocytes, is a heterodimeric molecule single-chain precursor form, and processing by specific
serine proteases into the two-chain form is coupled tocomposed of a 69 kD a-chain and a 34 kD b-chain [6–8].
The a-chain contains the N-terminal hairpin domain and its activation (Fig. 1A). HGF activator, a serine protease
responsible for activation of HGF, has structural similar-the subsequent four kringle domains, and the b-chain
contains a serine protease-like domain (Fig. 1A) [9, 10]. ity to blood coagulation factor XII [11]. Involvement
of urokinase-type plasminogen activator (uPA) in theThe kringle domain was initially found in serine proteases
involved in blood coagulation or thrombolysis, and HGF activation of pro-HGF was also reported [12].
Hepatocyte growth factor has multiple biological activi-has a 38% amino acid sequence homology to plasminogen.
Plasminogen is composed of a five kringle-containing ties on a wide variety of cells, including mitogenic, moto-
genic (enhancement of cell movement), morphogenic, andA-chain and B-chain of the serine protease catalytic sub-
unit, whereas HGF has no serine protease activity because anti-apoptotic activities (Fig. 1B) [13–19]. The motogenic
action of HGF was deduced from the unexpected findingamino acids are substituted in the catalytic center. HGF
is biosynthesized and secreted in a biologically inactive that characterization of scatter factor showed it to be
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identical to HGF [20–22]. Scatter factor was originally creasing cadherin-mediated cell–cell adhesion, respec-
tively. In addition to transphosphorylation-dependentidentified and purified as a fibroblast-derived epithelial
cell motility factor [23–25]. HGF affects cell–cell interac- signaling pathways, the induction of gene expression of
proteins involved in cell-associated proteolytic break-tion and cell–extracellular matrix (ECM) interaction and
stimulates or activates proteolytic networks involved in down of ECM components plays an important role in
branching tubulogenesis, including uPA, uPA receptor,the breakdown of ECM proteins [26–29]. Thus, typical
biological activities of HGF are involved in construction, and membrane-type 1 matrix metalloprotease (MT1-
MMP) [26–28]. In terms of anti-apoptosis, the activationremodeling, and protection of tissue structures during
development and regeneration. of PI-3 kinase and downstream Akt (protein kinase B)
[47] and the induction of Bcl-2/Bcl-xL are likely path-The receptor for HGF was identified in 1991 to be a
c-met protooncogene product [30, 31]. The c-Met receptor ways responsible for protection of cells from apoptosis
by HGF [48, 49].is composed of a 50 kD a-chain and a 145 kD b-chain
[32]. The a-chain is exposed extracellularly, while the The essential role of HGF and the c-Met receptor in
mammalian development was defined by disruption ofb-chain is a transmembrane subunit containing an intra-
cellular tyrosine kinase domain (Fig. 1B). Binding of HGF or the c-Met gene in mice; these animals died on
embryonic days 13 to 15 because of impaired organogene-HGF to the Met receptor induces activation of tyrosine
kinase, which results in the subsequent phosphorylation sis of the placenta and liver [50–52]. HGF is also involved
in the development of epithelial tissues, including theof C-terminally clustered tyrosine residues [33–36]. Phos-
phorylation of these tyrosine residues recruits intracellu- kidney, lung, mammary gland, and teeth, as a mediator in
epithelial–mesenchymal interactions for organogenesislar signaling molecules containing the src homology (SH)
domain, including Gab-1, phospholipase C-g (PLC-g), (discussed later in this article) [18, 53]. Concerning neu-
roneal development, HGF supports the projection ofRas-GTPase activating protein (Ras-GAP), phosphati-
dylinositol 4,5-bisphosphate 3-kinase (PI-3 kinase), c-Src, motor neurons [54].
Shp-2, Crk-2, and Grb-2 (Fig. 1B). Physiologically, HGF has an organotrophic role in the
Although the intracellular signaling pathways leading regeneration and protection of various organs, including
to specific or preferential activation of each biological the liver, lung, stomach, pancreas, heart, neurons, and
response (that is, mitogenic, motogenic, morphogenic, kidney [16, 55]. HGF levels increase in tissues and blood
or anti-apoptotic) driven by HGF-Met receptor coupling in response to various acute injuries and diseases. The
have yet to be fully defined, preferential activation of administration of HGF into laboratory animals has po-
signaling molecules and induction of gene expression tent therapeutic effects on various models of acute and
responsible for activation of specific cellular responses chronic organ diseases [part of related publications, ex-
are evident. Phosphotyrosine-dependent recruitment of cept for renal diseases; 48, 49, 56–76]. Likewise, HGF
the Grb-2/SOS complex activates Ras and subsequent has angiogenic activity for vascular endothelial cells and
phosphorylation events, including extracellular signal- induces extensive blood vessels when administered into
regulated kinase (ERK). Activation of the Ras-ERK ischemic tissue [65, 70, 76, 77]. On the other hand, HGF
pathway is required for cellular proliferation [33]. On regulates malignant behavior in various types of tumors,
the other hand, the association and tyrosine phosphory- including invasion, metastasis, and tumor angiogenesis
lation of Gab-1, a docking protein that couples the Met [27, 29, 67]. Likewise, aberrant activation of the c-Met
receptor with multiple signaling proteins such as PI-3 receptor is associated with tumorigenesis and malignant
kinase, PLC-g, Shp-2, and Crk-2, plays a definite role behavior of cancers [27, 29, 78]. The gain-of-function
in HGF-induced morphogenesis and cellular movement mutation in the c-met gene plays a determinant role in
[36, 37]. The expression of Gab-1 in Madin-Darby canine hereditary and some sporadic papillary renal carcinomas
kidney (MDCK) renal epithelial cells induces cell move- [79–81].
ment and branching tubulogenesis [37]. The association
of Gab-1 with Shp-2 protein tyrosine phosphatase, but
ACTIONS OF HGF IN RENALnot PI-3 kinase and Crk-2, is essential for inducing epi-
TISSUE ORGANIZATIONthelial branching tubulogenesis [36, 38]. Instead, activa-
Hepatocyte growth factor exerts mitogenic responsestion of PI-3 kinase and the Rho family GTPases (Rho,
in renal epithelial cells derived from distinct regions andRac, Cdc42) plays a critical role in HGF-induced cell
species, including rabbit and rat proximal tubular cellsmovement [39–42]. Rho GTPases regulate actin-related
[82–84] and rat glomerular epithelial cells [84]. Figurecytoskeletal organization and contractive force for cell
2A shows the effects of HGF and epidermal growthmovement and concomitant cell shape rearrangement.
factor (EGF) on DNA synthesis of cultured rabbit proxi-Likewise, HGF induces tyrosine phosphorylation of fo-
mal tubular cells [82]. HGF stimulates the proliferationcal adhesion kinase (FAK) [43, 44] and b-catenin [45, 46],
thereby enhancing the cell–ECM interaction and de- of renal epithelial cell lines, including a rat visceral glo-
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merular cell line [85], proximal tubular cell lines [86],
and a murine medullary collecting duct epithelial cell line
[87]. Likewise, HGF exhibits mitogenic action on renal
endothelial cells [88]. HGF has no apparent effect on rat
and human mesangial cell proliferation [84, 88, 89] and
is weakly mitogenic [89, 90], although mesangial cells do
express the c-Met receptor [88–90]. HGF diminished or
decreased stress fibers, focal contacts, and extracellular
fibronectin deposition in a murine mesangial cell culture,
thereby suggesting a reduced cell–substratum interaction
and enhanced cellular motility and remodeling in the
mesangial cell-related extracellular scaffold [89]. Like-
wise, enhancement of cell motility in renal epithelial cells
clearly has been evidenced in MDCK renal epithelial
cells [24, 25], and HGF stimulated Na,K-ATPase in a
renal tubular cell line [86].
The indispensable role of tubular cells for renal func-
tions depends on their multicellular architecture, that is,
branching tubules, and formation of branching tubulo-
genesis is involved in both renal regeneration and devel-
opment. Montesano, Schaller, and Orci, using a model of
epithelial–mesenchymal interaction, first demonstrated
that MDCK renal epithelial cells undergo branching tu-
bulogenesis in collagen gels in the presence of fibroblast-
derived conditioned medium [91], and the fibroblast-
derived epithelial morphogen proved to be HGF [92].
Figure 2B shows the induction of branching tubulogen-
esis by HGF in MDCK cells grown in a collagen gel.
Other growth factors such as EGF, fibroblast growth
factor-1 (FGF-1), FGF-2, FGF-7, insulin-like growth fac-
tor-I (IGF-I), IGF-II, and platelet-derived growth factor
(PDGF) do not induce branching tubulogenesis, whereas
transforming growth factor-b1 (TGF-b1) inhibits tubulo-
genesis in MDCK cells [92, 93]. Further insight into the
process of branching tubulogenesis reveals that branch-
ing tubules formed by HGF in MDCK cells retain a well-
defined apical-basolateral polarity [94] and that mem-
brane type-matrix metalloproteinase plays an essential
role in HGF-induced branching tubulogenesis [28]. Bowes
et al reported that HGF induces branching tubulogenesis
of renal proximal tubular cells in primary culture [95].
Fig. 2. (A) Mitogenic action of HGF (d) and epidermal growth factor
Other growth factors, including FGF-1, FGF-7, EGF, or (EGF; s) on cultured rabbit renal tubular cells. DNA synthesis of renal
tubular cells cultured in the absence or presence of HGF or EGF wasIGF-I, failed to induce this morphogenesis, however,
measured. (B) Induction of branching tubulogenesis by HGF in MDCKcombinations of these growth factors induced branching
renal epithelial cells grown in a collagen gel. Cells were grown in the
tubulogenesis [95]. These results indicate that morpho- absence or presence of 10 ng/mL HGF. (C) Potential roles of HGF in
epithelial–stromal and endothelial–mesangial interactions in the kidney.genic signal transduction through HGF-Met is redun-
dantly achieved by a combination of multiple signals, co-
operatively activated by sets of growth factors and their
receptors. While HGF is not the sole molecule capable of
induces the ureteric bud to bud and branch, and theinducing branching tubulogenesis in renal tubular cells,
ureteric bud, in turn, induces metanephric condensationit is definitely important for reconstructing the tubular
and the mesenchymal to epithelial cell conversion [96, 97].architecture during renal development and regeneration.
In the developing kidney, HGF is expressed in the meta-During renal development, a signal exchange between
nephric mesenchyme, and the Met receptor is expressedthe metanephric mesenchyme and the epithelial ureteric
bud plays a crucial role. The metanephric mesenchyme in the ureteric buds and in the epithelial cells of the
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Fig. 2. (Continued)
nephron [98–100]. Neutralizing antibody to HGF inhib- apoptotic action of Bcl-2/Bcl-xL, and Bag-1 expression
ited metanephric growth and morphogenesis in an organ in cells promotes the cell survival action of HGF [106].
culture of embryonic kidneys [99, 100]. In addition, HGF In tubular regions of the adult kidney, HGF is ex-
enhances differentiation of metanephric mesenchymal pressed in interstitial cells, presumably endothelial cells
cells into epithelial cells, whereas anti-HGF antibody and macrophages [107–109], while in the glomerulus, mes-
inhibits it, thereby indicating that HGF mediates the angial cells and endothelial cells express HGF [84, 86, 89,
mesenchymal to epithelial conversion of the metanephric 102]. Collectively, in the kidney, HGF seems to act on
mesenchyme [100, 101]. renal epithelial, endothelial, and mesangial cells through
Hepatocyte growth factor protects renal epithelial cells autocrine- or paracrine-related pathways (Fig. 2C).
from apoptotic cell death [102–105], and the anti-apoptotic
effect of HGF in renal epithelial cells is mediated by the
HGF IN RENOTROPIC SYSTEMSinduction of Bcl-xL expression and the phosphorylation
In addition to biological activities of HGF on renalof Bad, thereby inactivating this pro-apoptotic protein.
cells, involvement of HGF in renal regeneration has beenIt is noteworthy that Bag-1, a partner of Bcl-2/Bcl-xL, is
proposed based on findings that renal and plasma HGFspecifically associated with the c-Met receptor [106]. The
association of Bag-1 with Bcl-2/Bcl-xL enhances the anti- levels and c-Met receptor expression are regulated in
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Fig. 3. Possible pathways mediated by HGF for renal regeneration in response to acute renal injury. (A) Following renal injuries, HGF expression
is up-regulated in stromal cells in the kidney and in distant intact organs such as the lung, liver, and spleen. The right upper panel shows induction
of HGF mRNA in the lung following unilateral nephrectomy (UN) in rats. (B) Regulation of c-Met receptor activation in noninjured and injured
tissues. Change in cell–cell contact or junctional communication due to tissue injury may possibly regulate c-Met receptor function, such that HGF
exerts its biological activities in the injured tissue-specific manner.
response to renal injuries. A unilateral nephrectomy the kidney acting through paracrine and an autocrine
mechanisms and HGF produced in distant organs actingmodel has been used to study renotropic systems in com-
pensatory renal regeneration. HGF mRNA and protein through an endocrine mechanism (Fig. 3A).
The induction of HGF expression in distant intactlevels increase in the remaining kidney after unilateral
nephrectomy [110, 111]. Rapid increases in HGF mRNA organs suggests that a circulating factor(s) responsible
for induction of HGF may exist in the blood of animalsand/or protein levels in the kidney and plasma were seen
in various types of acute renal injuries induced by the with organ injury. Two studies demonstrated the pres-
ence of HGF-inducing factor in plasma or serum follow-administration of nephrotoxins such as HgCl2 and folic
acid, glycerol administration, renal ischemia, vitamin E ing the onset of acute organ injury. Plasma obtained
from laboratory animals with hepatic or renal injurydeficiency, and ureteral obstruction [107, 112–115]. Like-
wise, increases in blood HGF levels were noted in patients stimulated HGF expression in vivo and in vitro, and the
HGF inducer was shown to be proteinous factor [123].with acute renal failure [116, 117] and with acute renal
rejection after renal transplantation [118]. Similarly, HGF levels in sera were remarkably increased
in patients with acute renal failure, and sera from patientsAn induction of HGF mRNA in the kidney following
renal injuries indicates that the kidney is one source of with acute renal failure—but not sera from healthy vol-
unteers—strongly stimulated HGF production in mesan-HGF. In the kidney, stromal cells such as macrophages
and endothelial and mesangial cells express HGF [107, gial cells in culture [95].
Although the identification of HGF inducers in the109]; thus, HGF seems to act through paracrine- and
autocrine-related pathways. On the other hand, HGF plasma or serum remains to be addressed, several known
molecules are involved in regulating HGF expression.mRNA expression is up-regulated in distant intact or-
gans such as the lung, liver, and spleen, as well as the Among inflammatory mediators, interleukin-1 (IL-1),
interferon-g, tumor necrosis factor-a, and prostaglandininjured kidney following acute renal injury, including
unilateral nephrectomy (Fig. 3A), HgCl2 administration, E1 (PGE1) and PGE2 strongly activate gene expression
of HGF [124–126]. Likewise, FGF-1, FGF-2, PDGF, hep-and folic acid administration [114, 119–121]. It is note-
worthy that the induction of HGF mRNA expression in arin-binding EGF-like growth factor (HB-EGF), EGF,
and TGF-a induce HGF expression [127–130], whereasdistant noninjured organs was seen in cases of hepatic
and heart injuries [119–122]. These observations suggest TGF-b1 and angiotensin II strongly suppress the gene
expression of HGF [131–133]. Norepinephrine up-regu-that HGF increases in the blood circulation may be de-
rived from noninjured organs, as well as injured organs. lates HGF expression [134], whereas glucocorticoid neg-
atively regulates HGF expression [131]. The induction ofTherefore, renotropic systems supported by HGF may
involve two distinct pathways: HGF locally produced in HGF by inflammatory mediators implicates its coopera-
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tion with immune and regeneration/repair systems, while to two-chain HGF in injured organs. Since neutralizing
antibody to HGF-activator inhibited processing to theregulation of HGF by adrenal hormones implicates its
involvement in neuroendocrine and regeneration systems. active HGF, this enzyme is likely to be involved in the
injured tissue-specific activation of HGF [139]. Taken
together, these biological actions of HGF seem to be
INJURED TISSUE-SPECIFIC ACTIVATION OF
tightly regulated by distinct mechanisms involved in the
THE HGF–c-MET SYSTEM
modulation of receptor and ligand functions, such that
Given that HGF increases in the circulating blood, HGF exhibits biological actions in an injured tissue-spe-
could it nonselectively target both injured and nonin- cific manner.
jured tissues and cells? This may be an undesirable out-
come, as there would be an overgrowth of noninjured
HGF IN CHRONIC RENAL FAILURE/tissues and cells. However, this is not the case. Binding
RENAL FIBROSISof growth factors to their receptors induces down-regula-
tion of receptors because of endocytosis of the ligand- Progressive fibrosis in the kidney, liver, lung, heart,
muscle, bone marrow, and skin is both a major cause ofreceptor complex. Thus, analysis of down-regulation
allows one to track ligand-dependent activation of growth suffering and death and an important contributor to the
cost of health care, including hemodialysis. Dialysis mar-factor receptors. Analysis of the c-Met receptor in plasma
membranes of injured and noninjured tissues indicates ket estimates indicate that more than 400,000 patients
worldwide have undergone maintenance dialysis, andthat down-regulation of the c-Met receptor occurs in
injured but not in noninjured organs [135, 136]. Down- the number of patients with chronic renal disease is in-
creasing.regulation of the c-Met receptor occurs in the kidney
(but not in other organs) after unilateral nephrectomy, Chronic renal disease, characterized by a progressive
loss of parenchyma cells and renal fibrosis, representswhile it occurs in only the liver after hepatic injury. While
the mechanisms by which HGF selectively activates the the morphological equivalent of end-stage chronic renal
disease and occurs independently of the primary under-c-Met receptor in injured tissue are unknown, we can
speculate about the possible mechanisms. In mature he- lying disorder. The intricate architecture and filtrating
function of the kidney make it particularly vulnerablepatocytes in primary culture, HGF exerts mitogenic ac-
tion in a cell density-dependent manner. HGF potently to the consequences of fibrosis. Distinct lines of evidence
point to a causal relation between overexpression ofenhances DNA synthesis of hepatocytes cultured at a
low cell density but does not do so in the case of a high TGF-b and the onset of glomerular and tubulointerstitial
fibrosis [140–142]. Transgenic expression of TGF-b1 incell density [137]. Moreover, hepatocytes cultured at a
low cell density express a greater number of c-Met recep- mice leads to glomerulosclerosis and tubulointerstitial
fibrosis [143–146]. Overexpression of TGF-b1 or TGF-b2tors than when cultured at a high cell density. The rate
of internalization and recycling of the c-Met receptors by intravenous injection or in vivo gene transfection
showed that the kidney is highly susceptible to rapidon hepatocytes cultured at a low cell density was much
faster than that seen in the case of a high cell density fibrosis [147, 148]. Elevated expression of TGF-b was
noted in animal models of renal fibrosis [108, 109, 149–[138]. These results suggest that cell–cell adhesion and
communication may regulate the function and expres- 152] and in patients with glomerulonephritis, diabetic
nephropathy, and chronic allograft rejection [153–155].sion of the c-Met receptor, such that HGF exerts biologi-
cal activities in an injured tissue-specific manner (Fig. Biological neutralization of TGF-b1 with a proteoglycan
(decorin) prevented the increased production of ECM3B). On the other hand, Liu et al found that c-Met
mRNA expression and c-Met protein were markedly in glomeruli [156].
Biological actions of TGF-b are in accord with theincreased following injury to the kidney, where active
renal tissue repair/regeneration occurred, thereby sug- notion that overproduction of TGF-b is associated with
the onset of fibrotic disorders. TGF-b causes depositiongesting that local up-regulation of the c-Met receptor
may confer a specificity/susceptibility of HGF to renal of ECM proteins by simultaneously stimulating synthesis
of most ECM proteins and the production of inhibitorstissue [114].
The other potential mechanism for injured tissue-spe- of matrix-degrading proteases [140]. For epithelial and
endothelial cells, TGF-b induces growth arrest and in-cific activation of c-Met receptor may be associated with
proteolytic activation of single-chain pro-HGF to mature creases apoptotic cell death. TGF-b induces transdiffer-
entiation of mesangial cells and renal tubular epithelialHGF, which occurs in an injured tissue-specific manner
[121]. Although HGF increases in the liver, kidney, lung, cells into a-smooth muscle actin (a-SMA)-positive myo-
fibroblasts [157, 158]. Myofibroblasts play a definite roleand spleen in response to hepatic and renal injuries,
HGF remains as an inactive single chain in noninjured in the progression of renal fibrosis [159–161].
Until recently, it remained unclear whether HGF isorgans, while a significant portion of HGF is converted
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Fig. 4. Possible involvement of counterbalance between HGF and transforming growth factor-b (TGF-b) in the pathogenesis of chronic renal
failure/renal fibrosis. In the beginning of chronic injury, HGF expression is up-regulated, and the compensatory regenerative responses occur.
Repetitive injury results in overexpression TGF-b, a potent fibrogenic cytokine that induces extracellular matrix (ECM) accumulation and epithelial
and endothelial apoptosis. Since TGF-b suppresses HGF expression, HGF decreases in a reciprocal manner to the increase in TGF-b level during
the progression of chronic renal failure.
associated with accelerating or preventing the progres- fibrosis and dysfunction. TGF-b expression and ECM
accumulation were increased concomitantly with in-sion of renal fibrosis. However, recent studies clearly
showed that HGF has a role in protecting the nephrotic creases in tubular apoptosis and with decreases in tubular
proliferation. In contrast, the administration of HGFkidney from fibrosis [108, 109, 152, 162]. In the ICR
strain-derived glomerulonephritis (ICGN) mice, glomer- strongly suppressed TGF-b expression and prevented
the onset of renal fibrosis and chronic renal failure. Theseular injury is detectable from 3 weeks postnatally, while
renal dysfunction occurs from 12 to 14 weeks, a dysfunc- findings mean that the reciprocal balance between TGF-b
and HGF is closely associated with the pathogenesis andtion that coincides with tubular destruction and tubulo-
interstitial fibrosis. Because renal dysfunction in patients progression of renal fibrosis and that HGF plays a role
in protecting the kidney from fibrotic changes. In addi-with glomerular disease shows a better correlation with
tubulointerstitial fibrosis than with glomerulosclerosis, tion to the overexpression of TGF-b, a decrease in renal
HGF expression may be responsible for the occurrencethe ICGN mouse offers an appropriate model for patho-
physiological studies on human chronic renal disease. of chronic renal disease (Fig. 4).
It is noteworthy that a similar reciprocal change in theIn ICGN mice, the expression and the renal level of
TGF-b increase during progression of glomerular and expression of TGF-b and HGF was also noted during the
onset of tubulointerstitial fibrosis caused by unilateraltubulointerstitial fibrosis. Renal TGF-b levels correlate
fairly well with accumulation of type I collagen and fi- ureter-ligated obstruction in mice [109]. Likewise, sup-
pressive effects of endogenous HGF on chronic renalbronectin, and tubular apoptosis, whereas there is an in-
verse correlation with proliferation of tubular cells [108]. injury and renal fibrosis were demonstrated following
5/6 nephrectomy in rats [162]. The administration ofOn the other hand, HGF levels in the kidney are initially
higher than normal at the early stage of glomerulone- neutralizing anti-HGF antibody decreased the glomeru-
lar filtration rate and increased renal fibrosis, indicatingphritis, whereas there is a gradual decrease during pro-
gression of renal fibrosis, and the renal HGF level is that endogeneous HGF plays a role in protecting the
kidney from chronic renal injury and renal fibrosis. Al-lower than that in normal kidney at advanced stages of
the disease (Fig. 4). Thus, the renal HGF level correlates though involvement of the TGF-b–versus–HGF counter-
balance in the onset of chronic renal failure has yet towith a decrease in tubular proliferation and inversely
correlates with increase in the renal TGF-b level, ECM be noted in patients, this reciprocal expression pattern
was noted in the livers of patients with a chronic hepaticaccumulation, and tubular apoptosis. To address the
involvement of HGF in progression of renal fibrosis, disease [163, 164]. The increase in blood HGF levels in
patients with “chronic” renal failure is much less thanneutralizing anti-HGF antibody or recombinant HGF
was administered to ICGN mice. Neutralization of en- that in patients with “acute” renal failure [116, 165].
Given that a reciprocal balance between TGF-b anddogenous HGF strongly accelerated progression of renal
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Fig. 5. Preventive effect of HGF on acute
renal failure induced by administration of cis-
platin (A) or HgCl2 (B). Acute renal failure
was induced by cisplatin (15 mg/kg body
weight; A) or HgCl2 (7 mg/kg body weight;
B). Mice were injected with HGF (250 mg/kg
body weight) at 0.5 hours prior to administra-
tion of cisplatin or HgCl2 and 6, 12, 24, 36, 48
and 72 hours or 6, 12, 24, 36, and 48 hours
after the administration of cisplatin or HgCl2,
respectively. BUN (j) and serum creatinine
( ) at 96 (cisplatin) or 72 hours (HgCl2) were
measured. Each value represents the mean 6
SD [174].
HGF regulates the pathology of chronic renal disease, mice. In transgenic mice expressing HGF under control
how this reciprocal balance is achieved and how supple- of the metallothionein promotor (MT-HGF transgenic
mentation of exogenous HGF protects the kidney from mice), the mice developed tubular hyperplasia, glomeru-
chronic renal fibrosis and dysfunction deserve attention. losclerosis, and polycystic disease [169]. The same mice
First, TGF-b1 strongly suppresses expression of HGF also developed tumors of diverse origin, including the
mRNA [131–133], and this TGF-b1–induced suppression mammary gland, skin, and liver [170]. In contrast, in
of HGF expression explains why the overexpression of transgenic mice in which the HGF gene is expressed
TGF-b is associated with a decreased renal HGF expres- under control of a tissue-specific promoter, tumors did
sion. In the promoter region of the HGF gene, there is not develop. Transgenic mice expressing HGF under an
a TGF-b inhibitory element involved in TGF-b–induced albumin promoter (Alb-HGF transgenic mice) had a
transcriptional inhibition [166, 167], and TGF-b inhibits greatly increased potential for liver regeneration after
transcription of the HGF gene [168]. On the other hand, partial hepatectomy, but hepatocellular carcinoma did
how exogenous HGF suppresses renal TGF-b levels has not occur [171]. Keratinocyte-specific transgenic expres-
yet to be determined. HGF might possibly inhibit tran- sion of HGF affects melanocyte development, leading
scription of the TGF-b gene directly through the c-Met to melanocytosis, but tumors did not occur, even from
receptor, or the number of TGF-b–positive cells in the the skin [172]. Likewise, transgenic mice expressing HGF
kidney may be decreased. TGF-b and HGF are counter- in pancreatic b cells did not develop tumors, and the
acting in many multipotent biological actions. TGF-b mice were resistant to the diabetogenic effects of strepto-
induces growth arrest and/or apoptosis in renal tubular zotocin [173]. Abundant expression of HGF in various
cells and endothelial cells, but HGF exhibits mitogenic tissues and greatly increased systemic HGF levels fromand anti-apoptotic activities in these cell types. HGF
early developmental stages in MT-HGF transgenic miceinduces branching tubulogenesis in renal epithelial cells,
might affect differentiation, maturation, or epithelial re-while inhibition is seen with TGF-b. HGF stimulates or
newal, which results in renal pathology and tumor devel-induces proteases involved in the breakdown of ECM
opment in various tissues. In contrast, in vivo studiesproteins in several types of cells, including MT1-MMP,
analyzing the therapeutic potential of HGF in relevantuPA, and some matrix metalloproteases (MMPs) [26–29].
models for various diseases found no side effects thatIn contrast, TGF-b strongly stimulates the synthesis of
would limit the therapeutic usage of HGF or the HGFECM proteins and the production of inhibitors of prote-
gene [48, 49, 56–76, 108, 109, 152, 174–177]. Therefore,ases involved in ECM breakdown [140]. Consistently,
abundant expression of the HGF gene or abundant ad-HGF increased the expression of MMP-9, whereas HGF
ministration of HGF in which HGF levels reach muchdecreased the expression of tissue inhibitors of matrix
higher levels than are physiologically or pharmacologi-metalloptoteinase-1 (TIMP-1) and TIMP-2 in human
cally effective for a long period may potentially cause aproximal renal tubular cells in culture [162].
pathology, including renal pathology.
INVOLVEMENT OF ABERRANT HGF
POTENTIAL THERAPEUTIC APPLICATIONSEXPRESSION IN PATHOLOGY
Based on the renotropic and antifibrogenic actions ofInvolvement of an abundant expression of HGF in
pathology has been implicated from studies on transgenic HGF, the potential application of HGF for the treatment
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of renal diseases has been tested in various experimental
models. In a clinical setting, acute renal failure is often
caused by nephrotoxic drug administration (for example,
cisplatin, cyclosporine A, tacrolimus, and antibiotics)
and renal ischemia. Administration of cisplatin caused
acute renal failure in mice, whereas prophylactic admin-
istration prevented histologic destruction of renal tu-
bules and strongly suppressed the onset of acute renal
dysfunction (Fig. 5) [174]. Similarly, HGF prevented the
histologic destruction of renal tissue and the onset of
acute renal dysfunction caused by HgCl2 administration,
while it enhanced regeneration of tubular epithelial cells
[174]. Preventive effects of HGF in cases of acute tubular
injury and renal dysfunction were also seen in case of
cyclosporine A and tacrolimus (FK506) [176, 177]. Like-
wise, compared with control rats, rats administered HGF
postischemia had better renal function, reduced mortal-
ity, and a lesser degree of histologic injury when renal
ischemia was induced in rats by bilateral artery occlusion
[175]. All of these results suggest that HGF can be tested
for treatment of patients with acute renal failure or for
prophylaxis of acute renal failure potentially caused by
administration of nephrotoxic drugs.
Preventive actions of HGF on acute renal injury could
be potentially extended to chronic allograft nephropathy
after renal transplantation [178, 179]. Chronic allograft
nephropathy, characterized by renal fibrosis and dys-
function, often develops years after renal transplantation
and is a major cause of graft loss. In an experimental
model of chronic allograft nephropathy in rats, HGF was
administered daily for four weeks following engraftment.
In control rats without HGF-treatment, allografts showed
severe structural damage within one week. After a period
of quiescence, macrophage infiltration, elevated TGF-b1
expression, and myofibroblasts were seen at 16 weeks.
Fig. 6. Therapeutic effect of HGF on chronic renal failure/renal fibrosisAt 32 weeks, renal fibrosis and dysfunction occurred, and in ICGN mice. (A) Changes in TGF-b, collagen accumulation, tubular
the mortality rate was 50%. In contrast, there was little apoptosis, and tubular proliferation by HGF administration in kidneys
of ICGN mice, as determined by enzyme immunoassay (TGF-b) andearly injury and no later renal fibrosis or dysfunction, and
immunohistochemical analysis (collagen type I, apoptosis, and BrdU-all HGF-treated rats survived. Consistently, macrophage uptake). (B) Changes in BUN and serum creatinine (SCr) levels, without
infiltration and overexpression of TGF-b1 in the kidney (s) or with (d) HGF-treatment. When BUN levels reached 40 mg/dL,
HGF (500 mg/kg) or saline alone was given daily for 28 days [108, 152].were suppressed in HGF-treated animals. Since acute
ischemic injury during renal transplantation is associated
with the onset of chronic allograft nephropathy [180,
181], the effects of HGF on ischemic injury might prevent therapeutic efficacy of HGF in murine models of chronic
the onset of chronic allograft nephropathy. renal disease and tubulointerstitial fibrosis was remark-
Understanding the molecular and cellular mechanisms able [108, 109, 152]. In ICGN mice, recombinant HGF
leading to chronic renal disease has progressed; however, was administered for four weeks during middle- to end-
many chronic renal diseases remain incurable. As de- stage chronic renal disease.
scribed previously in this article, endogenous renal HGF In control mice not given HGF, molecular and cellular
levels decrease along with progression of renal fibrosis, events leading to end-stage chronic renal disease pro-
and neutralization of endogenous HGF accelerates the gressed during this period. Renal TGF-b levels, the num-
progression of renal fibrosis toward end-stage pathology. ber of a-SMA-positive myofibroblasts, type I collagen
Therefore, supplemental administration of HGF to com- and fibronectin accumulation and the number of tubular
pensate for decreased HGF levels may be therapeutic apoptosis increased, whereas the number of proliferating
tubular cells decreased. In contrast, in mice treated within cases of renal fibrosis and chronic renal failure. The
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Fig. 7. Putative mechanism for therapeutic effects of HGF on chronic renal failure/renal fibrosis. The supplement of HGF suppresses TGF-b
expression and enhances remodeling of renal tissues, including ECM degradation and epithelial and endothelial cell proliferation in fibrotic kidneys.
HGF may prevent cell death in epithelial and endothelial cells.
HGF, expression of TGF-b and PDGF, ECM accumula- remarkably increased in the cirrhotic liver, whereas the
tion, and the number of myofibroblasts and tubular apo- administration of HGF or the HGF gene induced the
ptosis decreased, whereas the number of regenerating remodeling of fibrotic/cirrhotic tissue toward a normal
tubular cells increased (Fig. 6A). Consistent with these hepatic structure with an accompanying marked de-
changes, the beneficial effects of HGF on the clinical crease in hepatic TGF-b expression. Although an associ-
outcome were apparent as decreases in levels of serum ation of TGF-b–versus–HGF counterbalance in patho-
creatinine, blood urea nitrogen (BUN), and urine albu- genesis and therapeutics of fibrotic disorders was first
min, and as a diminution in histologic renal injury (Fig. deduced from a murine model of chronic renal disease/
6B) [152]. It should be emphasized that serum creatinine, renal sclerosis, it is tempting to hypothesize that the
BUN and urine albumin levels, and histologic renal in- counterbalance between TGF-b and HGF has a determi-
jury in mice treated with HGF were less than such events nant role in the pathogenesis and therapeutics of a vari-
seen at the start of HGF administration. These results ety of fibrosis-related diseases.
indicate that treatment with HGF has therapeutic effects
in cases of chronic renal disease, rather than the HGF
CONCLUSION AND PERSPECTIVESsupplements merely retarding or inhibiting the progres-
The renotropic system underlies the vital ability of thesion of chronic renal disease (Fig. 7).
kidney to regenerate in response to injury or partialIn addition to renal fibrosis in ICGN mice, the adminis-
resection of the kidney. Several growth factors play rolestration of HGF attenuated tubulointerstitial fibrosis, de-
in renotropic systems [104, 183]; however, the specificcreased TGF-b expression and tubular apoptosis, and
role of each growth factor in renotropic systems has yetincreased tubular proliferation/regeneration following
to be fully clarified. HGF, a renotropic growth factor,unilateral ureter-ligated obstruction in mice [109]. Uni-
mediates epithelial–stromal and endothelial–mesangiallateral ureter-ligated obstruction has been widely used as
interactions for regeneration and maintenance of thea model to study the pathogenesis of tubulointerstitial fi-
kidney. In response to acute renal injury, the expressionbrosis. In addition, HGF inhibited the cyclosporine A- or
of HGF increases and HGF exerts renotropic actions.tacrolimus-induced endothelin-1 release from cultured
During progression of chronic renal failure/fibrosis, HGFrabbit proximal tubular cells [182]. Endothelin, which is
expression in the kidney decreases to a level much lowerinvolved in the pathogenesis of acute and chronic renal
than normal. The dominant expression of TGF-b overfailure, mediates the nephrotoxic side effects of cyclo-
HGF is associated with the progression of chronic renalsporine A and tacrolimus. Moreover, it is noteworthy
failure. HGF has preventive and therapeutic effects inthat HGF plays a role in protecting the liver and lungs
cases of acute and chronic renal failure by enhancingfrom liver cirrhosis and lung fibrosis in laboratory ani-
mals [57, 59, 61, 63, 71, 74]. The expression of TGF-b1 the reorganization of renal tissue following injuries and
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